Investors Cautioned About Fraud Inquiries Involving James Hardie and RxSight

New York, Monday, 25 August 2025.
August 25, 2025: Investors of James Hardie and RxSight were alerted to potential securities fraud. BFA Law is investigating for class actions. Response required by September 22, 2025.
Investigations into James Hardie Industries
James Hardie Industries plc (NYSE:JHX) is currently under scrutiny due to alleged misleading practices. BFA Law has launched a class action investigation aimed at probing potential securities fraud violations. The company’s challenges surfaced after it reported a 12% decline in North American net sales for Q1 2026, which was attributed to changes in inventory patterns rather than sustained demand [1].
Impact on James Hardie Stock
The revelation concerning the sales decline had an immediate impact on James Hardie’s stock price, which plummeted by over 34%—from $28.43 to $18.64—between August 19 and August 20, 2025. This substantial drop underscores investor concerns regarding the company’s reported performance and the potential ramifications of the investigation [1].
RxSight’s Legal Challenges
Similarly, RxSight, Inc. (NASDAQ:RXST) is facing a potential class action lawsuit for alleged securities fraud. The lawsuit accuses the company of failing to fully disclose challenges related to its flagship Light Adjustable Lens (LAL) product. Following a series of underwhelming revenue forecasts, RxSight’s stock fell precipitously by 38% in early July 2025, reflecting market apprehension about its future performance [2].
Deadline for Investors
Investors in both companies have been urged to respond promptly to participate in the class action suits. The deadline for RxSight investors to contact BFA Law is set for September 22, 2025. These legal proceedings highlight broader issues of corporate governance and the increasing vigilance of shareholder rights organizations [1][2].